ESMO 2021 - Agenus Presents Updates on Balstilimab Plus Zalifrelimab Combination
September 16 - September 21, 2021
-
724MO - Balstilimab (anti-PD-1) in Combination with Zalifrelimab (anti-CTLA-4): Final Results from a Phase II Study in Patients (pts) with Recurrent/metastatic (R/M) Cervical Cancer (CC), O'Malley, et al.
19 Sep 2021
-
818TiP - Balstilimab Alone or in Combination with Zalifrelimab as Second-line Treatment for Patients with Previously Treated Recurrent/metastatic Cervical Cancer (R/M CC): A Randomized, Placebo-controlled Phase II Trial (RaPiDS/GOG-3028), Leslie Randall, et al.
16 Sep 2021